Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for serious diseases, announced top-line ...
Harbour BioMed submits IND application for HBM9378/SKB378 to China NMPA to treat chronic obstructive pulmonary disease: Suzhou, China Monday, November 11, 2024, 17:00 Hrs [IST] Ha ...
Robles BioCeutics collaborates with BioCentrium to explore the molecular mechanisms behind Glowselle stem cell activator: San Diego Monday, November 11, 2024, 16:00 Hrs [IST] Robl ...
UDF to organize experts meeting towards creation of Indian Pharmaceutical Regulatory Service cadre: Shardul Nautiyal, Mumbai Monday, November 11, 2024, 16:45 Hrs [IST] New Delhi b ...
Exports of Ayush and herbal products for the first six months of the current fiscal has reported a 10.34 per cent growth, as ...
Dr Jayachandra Babu Ramapuram has been honoured with the prestigious AAPS Fellow Award at the American Association of Pharmaceutical Scientists (AAPS) annual meeting held in Salt Lake City, Utah. This ...
Leucine Rich Bio, now unveils its #HappyGutMission campaign an initiative designed to educate people on the critical role of gut health. This campaign has brought gut health to the forefront, offering ...
US FDA advisory panel votes in favour of IceCure's ProSense cryoablation benefit-risk profile in early-stage low risk breast cancer: Caesarea, Israel Monday, November 11, 2024, 15 ...
SystImmune, Inc (SystImmune), a clinical-stage biotechnology company, announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for BL-M17D1, ...
EMA's Committee for Veterinary Medicinal Products (CVMP) has issued the first certificate for a vaccine platform technology master file (vPTMF) which will support and accelerate the development and ...
Quantiphi and DDReg partner to transform regulatory reporting in life sciences through AI: Our Bureau, Bengaluru Monday, November 11, 2024, 13:45 Hrs [IST] Quantiphi, a global AI- ...
Nammi Therapeutics begins patient dosing in phase 1 study of QXL138AM for advanced solid tumours and multiple myeloma: Los Angeles Monday, November 11, 2024, 13:00 Hrs [IST] Nammi ...